[go: up one dir, main page]

DK1257648T4 - Antagonistiske selektive bindingsmidler af osteoprotegerin-bindingsprotein - Google Patents

Antagonistiske selektive bindingsmidler af osteoprotegerin-bindingsprotein Download PDF

Info

Publication number
DK1257648T4
DK1257648T4 DK01911158.2T DK01911158T DK1257648T4 DK 1257648 T4 DK1257648 T4 DK 1257648T4 DK 01911158 T DK01911158 T DK 01911158T DK 1257648 T4 DK1257648 T4 DK 1257648T4
Authority
DK
Denmark
Prior art keywords
ser
opgbp
gly
ala
val
Prior art date
Application number
DK01911158.2T
Other languages
English (en)
Other versions
DK1257648T3 (da
Inventor
Rajendra V Deshpande
John Kevin Sullivan
Anna Hitz
William J Boyle
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Priority claimed from PCT/US2001/005973 external-priority patent/WO2001062932A1/en
Application granted granted Critical
Publication of DK1257648T3 publication Critical patent/DK1257648T3/da
Publication of DK1257648T4 publication Critical patent/DK1257648T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (23)

1. Antistof eller antigenbindende domæne, som genkender en DE-epitop på humant osteoprotegerin-bindingsprotein (OPGbp), hvor a) en DE-epitop er en epitop, der omfatter et parti af aminosyresekvensen af et DE-område af humant OPGbp fra aminosyrerest 212 til aminosyre-rest 250 af sekvensen GFYYLYANICFRHHETSGDLATEYLQLMVYVTKTSIKIP, og b) DE-epitopen omfatter sekvensen DLATE, hvor antistoffet eller det antigenbindende domæne binder til aminosyresekvensen DLATE.
2. Antistof eller antigenbindende domæne ifølge krav 1, som binder til murint OPGbp omfattende aminosyresubstitutionerne S229D, V230L, P231A og D233E, men ikke binder til murint OPGbp, der mangler substitutionerne.
3. Antistof eller antigenbindende domæne ifølge krav 1, som inhiberer dannelsen eller aktiveringen af osteoklaster.
4. Antistof eller antigenbindende domæne ifølge krav 1, som inhiberer knogleresorption.
5. Antistof eller antigenbindende domæne ifølge krav 1, der omfatter en let kæde og en tung kæde, hvor den lette kæde omfatter aminosyresekvensen SEQ ID NO:45, og den tunge kæde omfatter aminosyresekvensen SEQ ID NO:51.
6. Antistof eller antigenbindende domæne ifølge et hvilket som helst af krav 1 -5, som er et kimært, CDR-podet, humaniseret eller humant antistof.
7. Isoleret nucleinsyremolekyle, der indkoder antistoffet eller det antigenbindende domæne ifølge et hvilket som helst af krav 1 til 6.
8. Ekspressionsvektor, der omfatter nucleinsyremolekylet ifølge krav 7.
9. Værtscelle, der omfatter ekspressionsvektoren ifølge krav 8.
10. Værtscelle ifølge krav 9, som er en CHO-celle.
11. Fremgangsmåde til fremstilling af et antistof, der omfatter dyrkning af værtscellen ifølge krav 10 under betingelser, som tillader ekspression af nucleinsyremolekylet.
12. Antistof ifølge krav 1 til 6, som er valgt blandt IgG, IgM, IgA, IgE og IgD.
13. Antistof ifølge krav 12, hvor isotypen er IgGi, lgG2, lgG3 eller lgG4.
14. Sammensætning omfattende antistoffet eller det antigenbindende domæne ifølge et hvilket som helst af krav 1 til 7 og en farmaceutisk acceptabel bærer.
15. Anvendelse af et antistof eller et antigenbindende domæne ifølge et hvilket som helst af krav 1 til 6 til fremstilling af en farmaceutisk sammensætning til inhi-bering af osteoklastdannelse eller -aktivering.
16. Anvendelse af et antistof eller et antigenbindende domæne ifølge et hvilket som helst af krav 1 til 6 til fremstilling af en farmaceutisk sammensætning til inhi-bering af knogleresorption.
17. Anvendelse af et antistof eller et antigenbindende domæne ifølge et hvilket som helst af krav 1 til 6 til fremstilling af en farmaceutisk sammensætning til forebyggelse eller behandling af tab af knoglemasse.
18. Anvendelse ifølge krav 17, hvor tab af knoglemasse skyldes osteoporose, metastase af cancer til knogle, rheumatoid arthritis, hypercalcæmi af malignitet og steroidinduceret osteoporose.
19. Anvendelse ifølge et hvilket som helst af krav 15 til 18, hvor en sammensætning omfattende mindst et middel, der er antiresorptivt i knogle, yderligere skal indgives.
20. Anvendelse ifølge krav 19, hvor det antiresorptive middel er østrogen, et bisphosphonat eller en selektiv østrogenreceptormodulator.
21. Anvendelse ifølge et hvilket som helst af krav 15 til 18, hvor en sammensætning, der omfatter et anabolt middel for knogle, yderligere skal indgives.
22. Anvendelse ifølge krav 21, hvor det anabole middel er parathyroidhormon eller et kompleks af insulinlignende vækstfaktor og insulinlignende vækstfaktorbindingsprotein.
23. Anvendelse ifølge et hvilket som helst af krav 15 til 18, hvor en interleukin-1 inhibitor eller en tumornekrosefaktor-alfa inhibitor yderligere skal indgives.
DK01911158.2T 2000-02-23 2001-02-23 Antagonistiske selektive bindingsmidler af osteoprotegerin-bindingsprotein DK1257648T4 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51113900A 2000-02-23 2000-02-23
US09/791,153 US20030103978A1 (en) 2000-02-23 2001-02-22 Selective binding agents of osteoprotegerin binding protein
PCT/US2001/005973 WO2001062932A1 (en) 2000-02-23 2001-02-23 Antagonistic selective binding agents of osteoprotegerin binding protein

Publications (2)

Publication Number Publication Date
DK1257648T3 DK1257648T3 (da) 2008-10-27
DK1257648T4 true DK1257648T4 (da) 2016-11-28

Family

ID=24033610

Family Applications (4)

Application Number Title Priority Date Filing Date
DK16198812.6T DK3184545T3 (da) 2000-02-23 2001-02-23 Antagonistiske selektive bindingsmidler af osteoprotegerin-bindingsprotein
DK01911158.2T DK1257648T4 (da) 2000-02-23 2001-02-23 Antagonistiske selektive bindingsmidler af osteoprotegerin-bindingsprotein
DK10013041.8T DK2305715T3 (da) 2000-02-23 2001-02-23 Monoklonalt antistof mod osteoprotegerinbindende protein
DK10010586.5T DK2330197T3 (da) 2000-02-23 2001-02-23 Antagonistiske selektive bindingsmidler af osteoprotegerin-bindingsprotein

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK16198812.6T DK3184545T3 (da) 2000-02-23 2001-02-23 Antagonistiske selektive bindingsmidler af osteoprotegerin-bindingsprotein

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK10013041.8T DK2305715T3 (da) 2000-02-23 2001-02-23 Monoklonalt antistof mod osteoprotegerinbindende protein
DK10010586.5T DK2330197T3 (da) 2000-02-23 2001-02-23 Antagonistiske selektive bindingsmidler af osteoprotegerin-bindingsprotein

Country Status (13)

Country Link
US (2) US20030103978A1 (da)
EP (5) EP2305715B1 (da)
JP (7) JP5279425B2 (da)
AT (1) ATE398676T2 (da)
CY (5) CY1108297T1 (da)
DK (4) DK3184545T3 (da)
ES (5) ES2307594T5 (da)
HK (1) HK1158696A1 (da)
LT (1) LT2105449T (da)
MX (2) MX363225B (da)
PT (5) PT2105449T (da)
SI (3) SI2105449T1 (da)
TW (1) TWI322182B (da)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
WO1998028426A2 (en) 1996-12-23 1998-07-02 Immunex Corporation Ligand for receptor activator of nf-kappa b, ligand is member of tnf superfamily
HU229476B1 (en) * 1997-04-15 2014-01-28 Daiichi Sankyo Company Antibodies against obm
US6316408B1 (en) * 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
SI0975754T2 (sl) * 1997-04-16 2016-04-29 Amgen Inc., Vezivni proteini in receptorji osteoprotegerina
ATE412746T1 (de) 1998-05-14 2008-11-15 Immunex Corp Verfahren zur hemmung der wirkung der osteoklasten
ES2675735T3 (es) 2001-06-26 2018-07-12 Amgen Inc. Anticuerpos para OPGL
CA2481074A1 (en) * 2002-04-05 2003-10-23 Amgen Inc. Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
US7052694B2 (en) * 2002-07-16 2006-05-30 Mayo Foundation For Medical Education And Research Dendritic cell potentiation
AU2004235595C1 (en) * 2003-04-30 2009-09-24 Japan Science And Technology Agency Human antihuman interleukin-18 antibody, fragment thereof and method of using the same
US20060099203A1 (en) * 2004-11-05 2006-05-11 Pease Larry R B7-DC binding antibody
WO2006017759A2 (en) * 2004-08-05 2006-02-16 Kirin Brewery Co., Ltd. Tumor endothelial marker-1 (tem1) binding antibodies and uses thereof
TW200736277A (en) * 2005-11-14 2007-10-01 Amgen Inc RANKL antibody-PTH/PTHrP chimeric molecules
US20080107597A1 (en) * 2006-01-12 2008-05-08 Anaptys Biosciences, Inc. Isolation of antibodies that cross-react and neutralize rankl originating from multiple species
US8039596B2 (en) 2008-02-05 2011-10-18 Bristol-Myers Squibb Company Alpha 5-beta 1 antibodies and their uses
EP2328615A2 (en) * 2008-08-20 2011-06-08 Centocor Ortho Biotech Inc. Engineered anti-il-13 antibodies, compositions, methods and uses
WO2010047515A2 (ko) 2008-10-20 2010-04-29 광주과학기술원 바이포달 펩타이드 바인더
US20120309934A1 (en) * 2009-12-11 2012-12-06 Gwangju Institute Of Science And Technology Intracelluar targeting bipodal peptide binder
JP5977814B2 (ja) 2011-04-08 2016-08-24 アムジエン・インコーポレーテツド 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を治療または改善する方法
MX2014009129A (es) 2012-01-26 2014-11-21 Amgen Inc Polipeptidos de factor 15 de diferenciacion de crecimiento (gdf-15).
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US9753030B2 (en) * 2013-03-06 2017-09-05 University of Pittsburgh—of the Commonwealth System of Higher Education Degradable carbon nanotube-containing biosensors and methods for target clinical marker detection
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
WO2015017710A1 (en) 2013-07-31 2015-02-05 Amgen Inc. Growth differentiation factor 15 (gdf-15) constructs
MX2016002870A (es) 2013-09-05 2017-02-23 Amgen Inc Moleculas que contienen fc que presentan perfiles de glicoforma predecibles, consistentes y reproducibles.
EP3143404B1 (en) 2014-05-16 2018-08-29 Amgen Inc. Assay for detecting th1 and th2 cell populations
GB201419094D0 (en) 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-TIM-3-antibodies
CN110294807B (zh) 2014-10-27 2023-05-12 新加坡科技研究局 抗tim-3抗体
KR20180030917A (ko) 2015-08-05 2018-03-26 얀센 바이오테크 인코포레이티드 항-cd154 항체 및 그의 사용 방법
JP2020513813A (ja) 2017-03-14 2020-05-21 アムジエン・インコーポレーテツド 細胞培養において産生される抗体の総非フコシル化グリコフォームの調節
CA3093853A1 (en) 2018-03-26 2019-10-03 Amgen Inc. Total afucosylated glycoforms of antibodies produced in cell culture
KR20200140878A (ko) 2018-04-09 2020-12-16 암젠 인크 성장 분화 인자 15 융합 단백질
AU2020355251A1 (en) 2019-09-26 2022-04-21 Amgen Inc. Methods of producing antibody compositions
EP4162257A1 (en) 2020-06-04 2023-04-12 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
WO2022032139A1 (en) * 2020-08-07 2022-02-10 Sorrento Therapeutics, Inc. Neutralizing antibodies that bind the sars-cov-2 s protein
JP2023548767A (ja) 2020-10-15 2023-11-21 アムジエン・インコーポレーテツド 抗体製造方法における相対不対グリカン
CA3222409A1 (en) 2021-06-07 2022-12-15 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
WO2023059607A1 (en) 2021-10-05 2023-04-13 Amgen Inc. Fc-gamma receptor ii binding and glycan content
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2024220916A1 (en) 2023-04-20 2024-10-24 Amgen Inc. Methods of determining relative unpaired glycan content
WO2025038600A1 (en) 2023-08-14 2025-02-20 Amgen Inc. Methods for reducing yellow color

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4699880A (en) * 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US6150090A (en) * 1986-01-09 2000-11-21 Massachusetts Institute Of Technology Nuclear factors associated with transcriptional regulation
US5106627A (en) * 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US4892538A (en) * 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5846534A (en) * 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
HU215434B (hu) 1988-05-27 1999-04-28 Synergen Inc. Eljárás interleukin-1 inhibitorok, ezeket kódoló DNS-szekvenciák, vektorok és gazdasejtek előállítására
US5011472A (en) * 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
JP2877509B2 (ja) 1989-05-19 1999-03-31 アムジエン・インコーポレーテツド メタロプロテイナーゼ阻害剤
EP0513334A4 (en) * 1990-11-30 1993-08-04 Celtrix Laboratories, Inc. Use of a bone morphogenetic protein in synergistic combination with tgf--g(b) for bone repair
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
MX9204303A (es) * 1991-07-23 1993-11-01 Rhone Poulenc Rorer Int Factor regulador del crecimiento de osteoclasto.
US5961974A (en) * 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
US5234784A (en) * 1992-04-01 1993-08-10 Eastman Kodak Company Method of making a projection viewable transparency comprising an electrostatographic toner image
US5578569A (en) * 1993-03-12 1996-11-26 Tam; Cherk S. Method of increasing bone growth
US5457035A (en) * 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
JPH09502614A (ja) * 1993-09-14 1997-03-18 メルク エンド カンパニー インコーポレーテッド 新規ヒト蛋白質チロシンホスファターゼをコードするｃＤＮＡ
US5641747A (en) * 1994-07-25 1997-06-24 Temple University-Of The Commonwealth System Of Higher Education Treatment of osteopetrotic diseases
US20030166097A1 (en) * 1995-03-15 2003-09-04 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
US7094564B1 (en) * 1995-03-15 2006-08-22 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
PT1666591E (pt) * 1995-06-29 2011-06-01 Immunex Corp Citoquina que induz apoptose
US6369027B1 (en) * 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US6613544B1 (en) * 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6046048A (en) * 1996-01-09 2000-04-04 Genetech, Inc. Apo-2 ligand
US5981220A (en) * 1996-03-27 1999-11-09 Human Genome Sciences, Inc. Epidermal differentiation factor
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
EP1995318A1 (en) * 1996-12-13 2008-11-26 Schering Corporation Mammalian cell surface antigens; related reagents
WO1998028423A2 (en) * 1996-12-20 1998-07-02 Board Of Regents, The University Of Texas System Compositions and methods of use for osteoclast inhibitory factors
WO1998028426A2 (en) * 1996-12-23 1998-07-02 Immunex Corporation Ligand for receptor activator of nf-kappa b, ligand is member of tnf superfamily
US6271349B1 (en) * 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
HU229476B1 (en) * 1997-04-15 2014-01-28 Daiichi Sankyo Company Antibodies against obm
AU7142498A (en) 1997-04-15 1998-11-11 Genetics Institute Inc. Secreted proteins and polynucleotides encoding them
US6316408B1 (en) * 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
US5843678A (en) * 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
SI0975754T2 (sl) * 1997-04-16 2016-04-29 Amgen Inc., Vezivni proteini in receptorji osteoprotegerina
AU7705098A (en) * 1997-05-29 1998-12-30 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like protein 8
US6087555A (en) * 1997-10-15 2000-07-11 Amgen Inc. Mice lacking expression of osteoprotegerin
US7063960B2 (en) * 1997-12-12 2006-06-20 The Rockefeller University Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereof
ATE412746T1 (de) * 1998-05-14 2008-11-15 Immunex Corp Verfahren zur hemmung der wirkung der osteoklasten
WO2000015807A1 (en) * 1998-09-15 2000-03-23 M & E Biotech A/S Method for down-regulating osteoprotegerin ligand activity
EP1368464B1 (en) * 2000-09-22 2007-07-04 Immunex Corporation Screening assays for agonists or antagonists of receptor activator of nf-kb
MXPA03010531A (es) * 2001-05-17 2004-07-01 Immunex Corp Uso terapeutico de antagonistas de rank.
MXPA03011270A (es) * 2001-06-06 2004-03-18 Immunex Corp Uso de antagonistas rank para tratar cancer.
ES2675735T3 (es) * 2001-06-26 2018-07-12 Amgen Inc. Anticuerpos para OPGL
US7084257B2 (en) * 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
CA2481074A1 (en) * 2002-04-05 2003-10-23 Amgen Inc. Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Also Published As

Publication number Publication date
PT2330197E (pt) 2014-10-15
MX2019002926A (es) 2019-07-18
JP5981981B2 (ja) 2016-08-31
HK1158696A1 (en) 2012-07-20
DK2305715T3 (da) 2017-03-13
SI2105449T1 (sl) 2019-09-30
ES2612124T3 (es) 2017-05-12
ES2505144T3 (es) 2014-10-09
LT2105449T (lt) 2019-08-12
US20140147444A1 (en) 2014-05-29
SI1257648T1 (sl) 2008-10-31
EP2305715A2 (en) 2011-04-06
ES2738798T3 (es) 2020-01-27
DK2330197T3 (da) 2014-12-15
CY1122686T1 (el) 2021-03-12
JP2018064555A (ja) 2018-04-26
JP5279425B2 (ja) 2013-09-04
EP2330197A2 (en) 2011-06-08
CY1121931T1 (el) 2020-10-14
DK3184545T3 (da) 2020-01-06
EP3184545B1 (en) 2019-10-16
EP2105449A3 (en) 2013-03-13
PT3184545T (pt) 2020-01-06
ATE398676T2 (de) 2008-07-15
SI2330197T1 (sl) 2015-02-27
JP2009060904A (ja) 2009-03-26
JP5747048B2 (ja) 2015-07-08
EP2330197A3 (en) 2013-05-29
ES2307594T5 (es) 2017-01-30
EP3613775A1 (en) 2020-02-26
JP2020062034A (ja) 2020-04-23
EP2305715B1 (en) 2016-12-07
CY1115634T1 (el) 2017-01-04
JP2015131800A (ja) 2015-07-23
US20030103978A1 (en) 2003-06-05
JP6453810B2 (ja) 2019-01-16
JP6647730B2 (ja) 2020-02-14
ES2307594T3 (es) 2008-12-01
EP2330197B1 (en) 2014-09-10
JP2019022486A (ja) 2019-02-14
MX363225B (es) 2019-03-15
ES2758881T3 (es) 2020-05-06
JP2016196476A (ja) 2016-11-24
EP2305715A3 (en) 2012-07-25
EP3184545A1 (en) 2017-06-28
CY1118462T1 (el) 2017-07-12
CY1108297T1 (el) 2014-02-12
PT2105449T (pt) 2019-10-18
PT1257648E (pt) 2008-09-19
TWI322182B (en) 2010-03-21
PT2305715T (pt) 2017-03-02
EP2105449B1 (en) 2019-07-03
JP2013135670A (ja) 2013-07-11
DK1257648T3 (da) 2008-10-27
EP2105449A2 (en) 2009-09-30

Similar Documents

Publication Publication Date Title
DK1257648T4 (da) Antagonistiske selektive bindingsmidler af osteoprotegerin-bindingsprotein
CA2400929C (en) Antagonistic selective binding agents of osteoprotegerin binding protein
US20030099647A1 (en) Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
AU2001238680B2 (en) Antagonistic selective binding agents of osteoprotegerin binding protein
DE DK et al. Thousand Oaks, CA 91320-1799 (US)
DE DK et al. ANTAGONISTISCHE SELEKTIVE BINDUNGSAGENZIEN DES OSTEOPROTEGERIN-BINDUNGSPROTEINS AGENTS DE LIAISON SELECTIFS ANTAGONISTES DE PROTEINE DE LIAISON D’OSTEOPROTEGERINE
DE DK et al. Designated Extension States
AU2001238680A1 (en) Antagonistic selective binding agents of osteoprotegerin binding protein
CA2502668C (en) Fully human antibody fab fragments with human interferon-gamma neutralizing activity